leadf
logo-loader
viewQ BioMed Inc.

Q BioMed to begin production of its potential coronavirus therapeutic with partner Mannin Research

Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive the group will begin production MAN-19, a clinical grade therapeutic intended to treat complications caused by the coronavirus.

Corin says the Phase 1 clinical trial, which will be conducted with technology partner Mannin Research, is slated to begin patient enrollment in February 2021.

Quick facts: Q BioMed Inc.

Price: 1.08 USD

OTCQB:QBIO
Market: OTCQB
Market Cap: $25.28 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Q BioMed gets US patent for its Uttrocide-B molecule as a potential liver...

Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive it has received a US patent for its Uttrocide-B molecule as a potential liver cancer treatment. Corin says the company now has the exclusive rights to the technology through an agreement with the Rajiv Gandhi Centre for Biotechnology,...

1 week, 6 days ago

2 min read